TY - JOUR
T1 - Noninvasive biomarkers of colorectal cancer
T2 - Role in diagnosis and personalised treatment perspectives
AU - Pellino, Gianluca
AU - Gallo, Gaetano
AU - Pallante, Pierlorenzo
AU - Capasso, Raffaella
AU - De Stefano, Alfonso
AU - Maretto, Isacco
AU - Malapelle, Umberto
AU - Qiu, Shengyang
AU - Nikolaou, Stella
AU - Barina, Andrea
AU - Clerico, Giuseppe
AU - Reginelli, Alfonso
AU - Giuliani, Antonio
AU - Sciaudone, Guido
AU - Kontovounisios, Christos
AU - Brunese, Luca
AU - Trompetto, Mario
AU - Selvaggi, Francesco
N1 - Publisher Copyright:
Copyright © 2018 Gianluca Pellino et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
PY - 2018
Y1 - 2018
N2 - Colorectal cancer (CRC) is the third leading cause of cancer-related deaths worldwide. It has been estimated that more than one-third of patients are diagnosed when CRC has already spread to the lymph nodes. One out of five patients is diagnosed with metastatic CRC. The stage of diagnosis influences treatment outcome and survival. Notwithstanding the recent advances in multidisciplinary management and treatment of CRC, patients are still reluctant to undergo screening tests because of the associated invasiveness and discomfort (e.g., colonoscopy with biopsies). Moreover, the serological markers currently used for diagnosis are not reliable and, even if they were useful to detect disease recurrence after treatment, they are not always detected in patients with CRC (e.g., CEA). Recently, translational research in CRC has produced a wide spectrum of potential biomarkers that could be useful for diagnosis, treatment, and follow-up of these patients. The aim of this review is to provide an overview of the newer noninvasive or minimally invasive biomarkers of CRC. Here, we discuss imaging and biomolecular diagnostics ranging from their potential usefulness to obtain early and less-invasive diagnosis to their potential implementation in the development of a bespoke treatment of CRC.
AB - Colorectal cancer (CRC) is the third leading cause of cancer-related deaths worldwide. It has been estimated that more than one-third of patients are diagnosed when CRC has already spread to the lymph nodes. One out of five patients is diagnosed with metastatic CRC. The stage of diagnosis influences treatment outcome and survival. Notwithstanding the recent advances in multidisciplinary management and treatment of CRC, patients are still reluctant to undergo screening tests because of the associated invasiveness and discomfort (e.g., colonoscopy with biopsies). Moreover, the serological markers currently used for diagnosis are not reliable and, even if they were useful to detect disease recurrence after treatment, they are not always detected in patients with CRC (e.g., CEA). Recently, translational research in CRC has produced a wide spectrum of potential biomarkers that could be useful for diagnosis, treatment, and follow-up of these patients. The aim of this review is to provide an overview of the newer noninvasive or minimally invasive biomarkers of CRC. Here, we discuss imaging and biomolecular diagnostics ranging from their potential usefulness to obtain early and less-invasive diagnosis to their potential implementation in the development of a bespoke treatment of CRC.
UR - http://www.scopus.com/inward/record.url?scp=85056222176&partnerID=8YFLogxK
U2 - 10.1155/2018/2397863
DO - 10.1155/2018/2397863
M3 - Review article
AN - SCOPUS:85056222176
SN - 1687-6121
VL - 2018
JO - Gastroenterology Research and Practice
JF - Gastroenterology Research and Practice
M1 - 2397863
ER -
